Conduct a prospective randomized clinical study on the efficacy and safety of computer modeling for optimal AAD selection in patients with recurrent AF after catheter ablation and evaluate the efficacy and safety of AAD simulations by comparing virtual AAD effect guided therapy and empirical AAD use in patients with recurrent AF after AF catheterization.
- Conditions
- Diseases of the circulatory system
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 300
1. The patients with 20~80 years old those recurred AF after catheter ablation
2. Patients who are suitable for sinus rhythm conversion and maintenance using AAD medications
3. Patients who had no history of serious side effects due to AAD medications before the procedure
1. Permanent AF Patients
2. AF associated with significant structural heart disease with severe anomaly or hemodynamic effects
3. Patients expected to have serious side effects when using AAD due to sinus node dysfunction
4. Severe liver or renal failure
5. Patients with past cardiac surgery history
6. Patients who are unable to oral medication or have electrolyte abnormalities
7. Patients with active internal bleeding
8. Contraindications for anticoagulant therapy (administered anticoagulant drugs to prevent cerebral infarction) or AAD
9. Valvular AF (mitral stenosis> grade 2, mechanical valve, mitral valve repair)
10. Severe concomitant illness
11. Patients expected to live for less than one year
12. Patients with drug or alcoholism
13. Those who cannot read the agreement (literacy, foreigners, etc.)
14. Patients judged to be inappropriate for participation in clinical trials by other researchers' judgment
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Atrial fibrillation or atrial tachycardia > 30 sec after medication within 2 year. 24-hour Holter ECG monitoring will be performed at 2 month and every 6 months, and ECG and monitoring with a Holter or an event recorder will be performed at any time if the patient complains of symptoms;Major cardiovascular event rate after medication - Death, Hospitalization, Systemic embolism related atrial fibrillation, Cerebrovascular disease, Stroke, Hemorrhage
- Secondary Outcome Measures
Name Time Method Comparison of cardioversion frequency, re-ablation(RFCA) and rate of re-hospitalization after medication(including re-hospitalization for complication by heart failure, embolism and hemorrhage) ;Frequency of drug complication after medication and Rate of discontinuation of medication due to complication